The assay functions as a diagnostic tool to identify PD-L1 levels in patients considering treatment with Roche’s cancer drug Tecentriq. PD-L1 is a protein that makes individuals more receptive to immunotherapy treatments.
Better insight into a patient’s PD-L1 levels can indicate the potential survival benefits associated with using Tecentriq as a treatment.
More articles on supply chain:
EpiPen price hikes cost DOD millions
Kits for care: How global sourcing helped Northside Hospital boost patient comfort
FDA approves Medtronic’s larger aortic valve replacement system
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
